We could not find any results for:
Make sure your spelling is correct or try broadening your search.
bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's reven... bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates. Show more
bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - BLUE PR Newswire NEW YORK, April 19, 2024 NEW YORK, April 19, 2024...
Class Action Filed Against bluebird bio, Inc. (BLUE) Seeking Recovery for Investors - Contact The Gross Law Firm PR Newswire NEW YORK, April 16, 2024 NEW YORK, April 16, 2024 /PRNewswire/ -- The...
Shareholders that lost money on bluebird bio, Inc.(BLUE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More PR Newswire NEW YORK, April 12, 2024 NEW YORK, April 12, 2024...
bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of 102,700 restricted stock units (“RSUs”) to...
bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm Before May 28, 2024 to Discuss Your Rights - BLUE PR Newswire NEW YORK, April 9, 2024 NEW YORK...
Shareholders that lost money on bluebird bio, Inc.(BLUE) should contact The Gross Law Firm about pending Class Action - BLUE PR Newswire NEW YORK, April 5, 2024 NEW YORK, April 5, 2024...
- Cash runway through Q1 2026 following announcement of a $175 million term loan facility with Hercules Capital - - 9 patient starts to date in 2024 (7 ZYNTEGLO, 2 SKYSONA); 85 to 105 patient...
bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss fourth quarter and 2023 annual results and business updates on March 26, 2024, at 8:00 a.m. ET. To...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.0864 | -8.30769230769 | 1.04 | 1.07 | 0.92 | 6772317 | 0.97838166 | CS |
4 | -0.2314 | -19.5274261603 | 1.185 | 1.42 | 0.92 | 5950942 | 1.13278004 | CS |
12 | -0.1864 | -16.350877193 | 1.14 | 1.92 | 0.879 | 8483546 | 1.27172902 | CS |
26 | -1.8964 | -66.5403508772 | 2.85 | 5.53 | 0.879 | 9931572 | 1.80243414 | CS |
52 | -2.8064 | -74.6382978723 | 3.76 | 5.53 | 0.879 | 6953332 | 2.3207736 | CS |
156 | -27.5464 | -96.6540350877 | 28.5 | 35.5883 | 0.879 | 4810733 | 4.99176934 | CS |
260 | -134.8764 | -99.2979459619 | 135.83 | 147.48 | 0.879 | 3323156 | 12.72874251 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions